Exagen engages in the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling differential diagnosis and improving therapeutic intervention. Co. commercializes a portfolio of testing products under its AVISE® brand, several of which incorporate Cell-Bound Complement Activation Products (CB-CAPs) technology. CB-CAPs assess the activation of the complement system, a biological pathway that is implicated across various autoimmune and autoimmune-related diseases. Co.'s testing product, AVISE® CTD, enables differential diagnosis for patients presenting with symptoms indicative of connective tissue diseases and other diseases with overlapping symptoms. We show 10 historical shares outstanding datapoints in our coverage of XGN's shares outstanding history.
Understanding the changing numbers of XGN shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like XGN versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching XGN by allowing them to research XGN shares outstanding history
as well as any other stock in our coverage universe. |
Free XGN Email Alerts:
Video: Shares Outstanding Importance
